Recent advances in the detection of prostate cancer using epigenetic markers in commonly collected laboratory samples

Adam Maxwell, Christopher R. McCudden, Frank Wians, Monte Willis

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Prostate cancer is the most common malignancy diagnosed in men and is the second leading cause of cancer-related death in the United States. The slower progression of prostate cancer compared with other types of cancers makes it particularly amenable to early diagnosis with significantly better outcomes. Currently, screening with a digital rectal exam and the detection of an elevated prostate-specific antigen (PSA) constitutes the standard of care. However, PSA testing can inappropriately miss some patients with cancer and falsely identify healthy patients to be at an increased risk of prostate cancer, leading to unnecessary biopsies. This has led to the search for alternative and/or adjunct biomarkers of prostate cancer. This article discusses how the detection of epigenetic biomarkers, specifically hypermethylation of specific DNA regions (CpG islands), is being used experimentally for the first time for the early detection of prostate cancer in commonly used laboratory specimens including plasma, serum, and urine to improve PCa diagnostics.

Original languageEnglish (US)
Pages (from-to)171-178
Number of pages8
JournalLaboratory Medicine
Volume40
Issue number3
DOIs
StatePublished - Dec 1 2009
Externally publishedYes

Fingerprint

Biomarkers
Prostate-Specific Antigen
Epigenomics
Prostatic Neoplasms
CpG Islands
Biopsy
Screening
Neoplasms
Plasmas
DNA
Testing
Standard of Care
Early Detection of Cancer
Early Diagnosis
Urine
Serum

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Recent advances in the detection of prostate cancer using epigenetic markers in commonly collected laboratory samples. / Maxwell, Adam; McCudden, Christopher R.; Wians, Frank; Willis, Monte.

In: Laboratory Medicine, Vol. 40, No. 3, 01.12.2009, p. 171-178.

Research output: Contribution to journalReview article

Maxwell, Adam ; McCudden, Christopher R. ; Wians, Frank ; Willis, Monte. / Recent advances in the detection of prostate cancer using epigenetic markers in commonly collected laboratory samples. In: Laboratory Medicine. 2009 ; Vol. 40, No. 3. pp. 171-178.
@article{02d56fdc99784acfa4ba5eba26cb8364,
title = "Recent advances in the detection of prostate cancer using epigenetic markers in commonly collected laboratory samples",
abstract = "Prostate cancer is the most common malignancy diagnosed in men and is the second leading cause of cancer-related death in the United States. The slower progression of prostate cancer compared with other types of cancers makes it particularly amenable to early diagnosis with significantly better outcomes. Currently, screening with a digital rectal exam and the detection of an elevated prostate-specific antigen (PSA) constitutes the standard of care. However, PSA testing can inappropriately miss some patients with cancer and falsely identify healthy patients to be at an increased risk of prostate cancer, leading to unnecessary biopsies. This has led to the search for alternative and/or adjunct biomarkers of prostate cancer. This article discusses how the detection of epigenetic biomarkers, specifically hypermethylation of specific DNA regions (CpG islands), is being used experimentally for the first time for the early detection of prostate cancer in commonly used laboratory specimens including plasma, serum, and urine to improve PCa diagnostics.",
author = "Adam Maxwell and McCudden, {Christopher R.} and Frank Wians and Monte Willis",
year = "2009",
month = "12",
day = "1",
doi = "10.1309/LMMY5RHJL9UD6RGS",
language = "English (US)",
volume = "40",
pages = "171--178",
journal = "Laboratory Medicine",
issn = "0007-5027",
publisher = "American Society of Clinical Pathologists",
number = "3",

}

TY - JOUR

T1 - Recent advances in the detection of prostate cancer using epigenetic markers in commonly collected laboratory samples

AU - Maxwell, Adam

AU - McCudden, Christopher R.

AU - Wians, Frank

AU - Willis, Monte

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Prostate cancer is the most common malignancy diagnosed in men and is the second leading cause of cancer-related death in the United States. The slower progression of prostate cancer compared with other types of cancers makes it particularly amenable to early diagnosis with significantly better outcomes. Currently, screening with a digital rectal exam and the detection of an elevated prostate-specific antigen (PSA) constitutes the standard of care. However, PSA testing can inappropriately miss some patients with cancer and falsely identify healthy patients to be at an increased risk of prostate cancer, leading to unnecessary biopsies. This has led to the search for alternative and/or adjunct biomarkers of prostate cancer. This article discusses how the detection of epigenetic biomarkers, specifically hypermethylation of specific DNA regions (CpG islands), is being used experimentally for the first time for the early detection of prostate cancer in commonly used laboratory specimens including plasma, serum, and urine to improve PCa diagnostics.

AB - Prostate cancer is the most common malignancy diagnosed in men and is the second leading cause of cancer-related death in the United States. The slower progression of prostate cancer compared with other types of cancers makes it particularly amenable to early diagnosis with significantly better outcomes. Currently, screening with a digital rectal exam and the detection of an elevated prostate-specific antigen (PSA) constitutes the standard of care. However, PSA testing can inappropriately miss some patients with cancer and falsely identify healthy patients to be at an increased risk of prostate cancer, leading to unnecessary biopsies. This has led to the search for alternative and/or adjunct biomarkers of prostate cancer. This article discusses how the detection of epigenetic biomarkers, specifically hypermethylation of specific DNA regions (CpG islands), is being used experimentally for the first time for the early detection of prostate cancer in commonly used laboratory specimens including plasma, serum, and urine to improve PCa diagnostics.

UR - http://www.scopus.com/inward/record.url?scp=77951959307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951959307&partnerID=8YFLogxK

U2 - 10.1309/LMMY5RHJL9UD6RGS

DO - 10.1309/LMMY5RHJL9UD6RGS

M3 - Review article

AN - SCOPUS:77951959307

VL - 40

SP - 171

EP - 178

JO - Laboratory Medicine

JF - Laboratory Medicine

SN - 0007-5027

IS - 3

ER -